Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada

MLA

Danuta M Skowronski, et al. “Comparative Single-Dose MRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.” The Journal of Infectious Diseases, vol. 226, Jan. 2022, pp. 485–96. EBSCOhost, https://doi.org/10.1093/infdis/jiac023.

APA

Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Hind Sbihi, Chris D Fjell, Eleni Galanis, Monika Naus, David M Patrick, Shiraz El Adam, May A Ahmed, Shinhye Kim, Bonnie Henry, Linda M N Hoang, Manish Sadarangani, Agatha N Jassem, & Mel Krajden. (2022). Comparative Single-Dose mRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada. The Journal of Infectious Diseases, 226, 485–496. https://doi.org/10.1093/infdis/jiac023

Chicago

Danuta M Skowronski, Solmaz Setayeshgar, Macy Zou, Natalie Prystajecky, John R Tyson, Hind Sbihi, Chris D Fjell, et al. 2022. “Comparative Single-Dose MRNA and ChAdOx1 Vaccine Effectiveness Against Severe Acute Respiratory Syndrome Coronavirus 2, Including Variants of Concern: Test-Negative Design, British Columbia, Canada.” The Journal of Infectious Diseases 226 (January): 485–96. doi:10.1093/infdis/jiac023.